You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亚盛医药(06855.HK)在研淋巴瘤新药获美国孤儿药资格认证
阿思达克 01-29 08:20
亚盛医药(06855.HK)公布,美国食品和药品监督管理局(FDA)日前授予公司在研原创新药Bcl-2抑制剂APG-2575孤儿药资格认定,用於治疗滤泡性淋巴瘤(FL)。

这是APG-2575继华氏巨球蛋白血症(WM)、慢性淋巴细胞白血病(CLL)、多发性骨髓瘤(MM)和急性髓系白血病(AML)适应症之後,获得的第五项FDA授予的孤儿药资格认定。目前亚盛医药共有4个在研新药获得共10项FDA孤儿药认证,创中国药企之最。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account